Sennoside B | CAS:128-57-4 | Manufacturer ChemFaces

Sennoside B

ChemFaces products have been cited in many studies from excellent and top scientific journals

Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC

How to Order

Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com

Delivery time

Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal

Citing Use of our Products

More Impact Factor than five Cite...

* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.

According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.

Size /Price /Stock	10 mM * 1 mL in DMSO / $18.1 / In-stock
Other Packaging	*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap

Featured Products

More...

Aristolochic acid A

Catalog No: CFN99505
CAS No: 313-67-7
Price: $80/20mg

Schizandrin B

Catalog No: CFN99923
CAS No: 61281-37-6
Price: $50/20mg

Glycitin

Catalog No: CFN99105
CAS No: 40246-10-4
Price: $70/20mg

Oxymatrine

Catalog No: CFN99805
CAS No: 16837-52-8
Price: $40/20mg

Taraxasterol acetate

Catalog No: CFN97104
CAS No: 6426-43-3
Price: $/mg

Dehydromiltirone

Catalog No: CFN98532
CAS No: 116064-77-8
Price: $438/5mg

Calycosin-7-O-beta-D-glucoside

Catalog No: CFN99141
CAS No: 20633-67-4
Price: $80/20mg

Purpurin

Catalog No: CFN92566
CAS No: 81-54-9
Price: $30/20mg

Gracillin

Catalog No: CFN98537
CAS No: 19083-00-2
Price: $80/20mg

Magnolignan A

Catalog No: CFN96188
CAS No: 93673-81-5
Price: $318/10mg

Description:

Sennoside B, a major purgative component, has a potential utility in the treatment of proliferative diseases, through inhibiting PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway. It and sennoside A also possess significant gastroprotective activities .

Targets:

PGE | ATPase | Potassium Channel | PDGFR | STAT | ERK | Akt

In vitro:

Life Sci. 2009 Jun 19;84(25-26):915-22.

Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells.[Pubmed: 19393247]

AIMS: To address the possibility that Sennoside B inhibition of cell proliferation is mediated via interference with platelet-derived growth factor (PDGF) signaling. MAIN METHODS: Human osteosarcoma MG63 cells were treated with PDGF in the presence or absence of Sennoside B. Activation of the PDGF signaling pathway was monitored using western immunoblotting with specific antibodies against the PDGF receptor, phosphotyrosine and components of the downstream signaling cascade. Activation of cell metabolism and proliferation was assessed by chromogenic reduction of MTT. KEY FINDINGS: Sennoside B was found to inhibit PDGF-BB-induced phosphorylation of the PDGF receptor (PDGFR) in human MG63 osteosarcoma cells. Downstream signaling was also affected; pre-incubation of PDGF-BB with Sennoside B inhibited the phosphorylation of pathway components including Ak strain To address the possibility that Sennoside B inhibition of cell proliferation is mediated via interference with platelet-derived growth factor (PDGF) signaling.
METHODS AND RESULTS:
Human osteosarcoma MG63 cells were treated with PDGF in the presence or absence of Sennoside B. Activation of the PDGF signaling pathway was monitored using western immunoblotting with specific antibodies against the PDGF receptor, phosphotyrosine and components of the downstream signaling cascade. Activation of cell metabolism and proliferation was assessed by chromogenic reduction of MTT. Sennoside B was found to inhibit PDGF-BB-induced phosphorylation of the PDGF receptor (PDGFR) in human MG63 osteosarcoma cells. Downstream signaling was also affected; pre-incubation of PDGF-BB with Sennoside B inhibited the phosphorylation of pathway components including Ak strain transforming protein (AKT), signal transducer and activator of transcription 5 (STAT-5) and extracellular signal-regulated kinase 1/2 (ERK1/2). Further, we found that Sennoside B can bind directly to the extracellular domains of both PDGF-BB and the PDGF-beta receptor (PDGFR-beta). The effect was specific for Sennoside B; other similar compounds including aloe-emodin, rhein and the meso isomer (sennoside A) failed to inhibit PDGFR activation or downstream signaling. Sennoside B also inhibited PDGF-BB stimulation of MG63 cell proliferation.
CONCLUSIONS:
These results indicate that Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway. Sennoside B is therefore of potential utility in the treatment of proliferative diseases in which PDGF signaling plays a central role.

In vivo:

J Drug Target. 2015 Feb;23(2):180-90.

Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent.[Pubmed: 25330022]

Necrosis-avid agents are a class of compounds that selectively accumulate in the necrotic tissues after systemic administration, which can be used for in vivo necrosis imaging and targeted therapies.
METHODS AND RESULTS:
In order to search for a necrosis-avid tracer agent with improved drugability, we labelled iodine-131 on Sennoside B (SB) as a naturally occurring median dianthrone compound. The necrosis targetability and clearance properties of (131)I-Sennoside B were evaluated in model rats with liver and muscle necrosis. On SPECT/CT images, a "hot spot" in the infarcted liver lobe and necrotic muscle was persistently observed at 24 h and 72 h post-injection (p.i.). Gamma counting of the tissues of interest revealed a radioactivity ratio of necrotic to viable liver at 4.6 and 3.4 and of necrotic to viable muscle at 7.0 and 8.8 at 24 h and 72 h p.i., respectively. The good match of autoradiographs and fluoromicroscopic images with corresponding histochemical staining suggested preferential uptake of (131)I-Sennoside B in necrotic tissue. Pharmacokinetic study revealed that (131)I-Sennoside B has an elimination half-life of 8.6 h.
CONCLUSIONS:
This study indicates that (131)I-Sennoside B shows not only prominent necrosis avidity but also favourable pharmacokinetics, which may serve as a potential necrosis-avid diagnostic agent for assessment of tissue viability.

Sennoside B Description

Source:	The leaves of Cassia angustifolia.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Storage:	Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
After receiving:	The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Animal Research:

Biomol Ther (Seoul). 2015 Sep; 23(5): 458–464.

Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H+/K+-ATPase.[Pubmed: 26336586 ]

Sennoside A (erythro) and Sennoside B (threo) are dianthrone glycosides and diastereomers. We investigated their abilities to prevent the gastric lesions associated with diseases, such as, gastritis and gastric ulcer.
METHODS AND RESULTS:
To elucidate their gastroprotective effects, the inhibitions of HCl•EtOH-induced gastritis and indomethacin-induced gastric ulcers were assessed in rats. It was observed that both sennoside A and Sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump). In a rat model, both compounds reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner. In a gastric emptying and intestinal transporting rate experiment, both sennoside A and Sennoside B accelerated motility.
CONCLUSIONS:
Our results thus suggest that sennoside A and Sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

Structure Identification:

Wei Sheng Yan Jiu. 2011 May;40(3):355-7.

[Determination of sennoside A and sennoside B simultaneously in health food by HPLC].[Pubmed: 21695913]

To develop an analytical method for determination of sennoside A and Sennoside B simultaneously in health food by high performance liquid chromatography (HPLC).
METHODS AND RESULTS:
Samples were extracted by ultrasound extraction and determined by HPLC with a UV detector. Using a Synergi Hydro-RP (250 mm x 4.6 mm, 4 microm) column and a mixture of CH3CN: 1.0% CH3COOH (17:83) as mobile phase for separation. The detection wavelength was at 270 nm. The contents were calculated with an external standard. The linearity was good in the ranges of 1.40 - 28.0 microg/ml for sennoside A and 1.45 - 29.0 microg/ml for Sennoside B. The average recovery rates of sennoside A and Sennoside B were 85.2% -97.2% and 86.1% -96.2%. The RSD was 7.5% and 6.8%, the limit of detection was 0.8 mg/kg and 0. 6 mg/kg, and the limit df quantification was 2.1 mg/kg and 2.0 mg/kg for sennoside A and Sennoside B respectively.
CONCLUSIONS:
The method is simple, accurate and suitable for the determination of sennoside A and Sennoside B in health food.

Product Name	Sennoside B
Price:	$40 / 20mg
CAS No.:	128-57-4
Catalog No.:	CFN99904
Molecular Formula:	C₄₂H₃₈O₂₀
Molecular Weight:	862.74 g/mol
Purity:	>=98%
Type of Compound:	Anthraquinones
Physical Desc.:	Yellow powder
Source:	The leaves of Cassia angustifolia.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Download:	COA MSDS SDF Manual
Similar structural:	Comparison (Web) (SDF)
Guestbook:

Size /Price /Stock	10 mM * 100 uL in DMSO / Inquiry / In-stock 10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries	Anti-proliferation Compound Library Purgative Compound Library Gastro-protective Compound Library Anthraquinones Compound Library STAT Inhibitor Library Potassium Channel Inhibitor Library PGE Inhibitor Library PDGFR Inhibitor Library ERK Inhibitor Library ATPase Inhibitor Library Akt Inhibitor Library

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	1.1591 mL	5.7955 mL	11.591 mL	23.182 mL	28.9774 mL
5 mM	0.2318 mL	1.1591 mL	2.3182 mL	4.6364 mL	5.7955 mL
10 mM	0.1159 mL	0.5795 mL	1.1591 mL	2.3182 mL	2.8977 mL
50 mM	0.0232 mL	0.1159 mL	0.2318 mL	0.4636 mL	0.5795 mL
100 mM	0.0116 mL	0.058 mL	0.1159 mL	0.2318 mL	0.2898 mL

CFN99905	Sennoside C	37271-16-2	848.76	C₄₂H₄₀O₁₉
CFN99906	Sennoside D	37271-17-3	848.76	C₄₂H₄₀O₁₉
CFN97845	Floribundone 1	118555-84-3	566.52	C₃₂H₂₂O₁₀
CFN93055	Protohypericin	548-03-8	506.46	C₃₀H₁₈O₈
CFN99188	Hypericin	548-04-9	504.45	C₃₀H₁₆O₈
CFN99591	Pseudohypericin	55954-61-5	520.44	C₃₀H₁₆O₉
CFN90677	Protopseudohypericin	54328-09-5	522.46	C₃₀H₁₈O₉
CFN99597	Sennidin A	641-12-3	538.46	C₃₀H₁₈O₁₀
CFN99598	Sennidin B	517-44-2	538.46	C₃₀H₁₈O₁₀
CFN99903	Sennoside A	81-27-6	862.74	C₄₂H₃₈O₂₀